Drug Enforcement Administration; December 7, 2023
Tag: DEA
t-boc norfentanyl
US Drug Enforcement Administration; SWGDRUG; 2023
Examination of Latent Print Evidence
MDMB-4en-PINACA
US Drug Enforcement Administration; SWGDRUG; 2023
Standard Operating Procedure for the Analysis of Suspected Methamphetamine
Examination of Friction Ridge Evidence
6-MAPB
US Drug Enforcement Administration; SWGDRUG; 2023
3-Chloro-N,N-dimethylcathinone
US Drug Enforcement Administration; SWGDRUG; 2023
Analysis of Drug Evidence
U.S. Drug Enforcement Administration; November 2023
NFLIS-Drug Brief: Substances Co-Reported with Fentanyl in NFLIS-Drug and DEA-Tox, January 2013–June 2023
Diversion Control Division
U.S. Department of Justice, U.S. Drug Enforcement Administration; November 2023
DEA TOX: Quarterly Report – Second Quarter 2023
Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I
Drug Enforcement Administration; October 25, 2023
Sourcing Xylazine
El Paso Illicit Drug Lab
Joint Intrepid Laboratory; Drug Enforcement Administration; October 2023
2022 Medical Examiner and Coroner Survey Report
National Forensic Laboratory Information System: NFLIS-Drug 2022 annual report
Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I
DEA; September 22, 2023
Schedules of Controlled Substances: Placement of Metonitazene in Schedule I
DEA; August 18, 2023
Fentanyl Used in Vape Pens
DEA Bulletin; San Diego Field Division; September 2020
Counterfeit Controlled Prescription Drug Availability in Pennsylvania & Delaware
DEA Intelligence Report; September 2020
Standard Operating Procedure for the Analysis of Suspected Cannabis Plant Material
Standard Operating Procedure for the Analysis of Cannabis Liquids and Extracts
Standard Operating Procedure for the Analysis of Suspected Natural and Synthetic Opioids
Standard Operating Procedure for the Analysis of Suspected Cocaine
Drug Enforcement Administration Office of Forensic Sciences
DEA Office of Forensic Sciences; 2023
DEA Tox – Quarterly Report – 1st Quarter 2023
DEA TOX – 2022 Annual Report
Schedules of Controlled Substances: Placement of Nine Specific Fentanyl-Related Substances in Schedule
DEA; April 13, 2023
Designation of Halides of 4-Anilinopiperidine as List I Chemicals
DEA; April 14, 2023
Announcement of an Emerging Compound – Medetomidine
National Forensic Laboratory Information System
DEA Synth-Opioids Real-time Communication Network; NFLIS; March 2023 (retrieved from https://synthopioids.nflis.deadiversion.usdoj.gov/ with permission from Agnes Winokur
Schedules of Controlled Substances: Placement of Brorphine in Schedule I
DEA; March 6, 2023
DEA Tox – Quarterly Report – 4th Quarter
Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I
Summary of Validated Quantitative Methods
DEA; 40pp; December 2022
Summary of Validated Qualitative Methods
Drugs of Abuse – A DEA Resource Guide – 2022 Edition
DEA Tox – Toxicology Testing Program
DEA; Third Quarter; 2022
Schedules of Controlled Substances: Placement of Mesocarb in Schedule I
DEA; November 22, 2022
Schedules of Controlled Substances: Placement of Zipeprol in Schedule I
DEA; November 21, 2022
Schedules of Controlled Substances: Placement of Amineptine in Schedule I
DEA; November 17, 2022
Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV
DEA; September 30, 2022
NFLIS-Drug Snapshot
National Forensic Laboratory Information System
DEA Tox – Quarterly Report – 2nd Quarter
Schedules of Controlled Substances: Placement of Serdexmethylphenidate in Schedule IV
DEA; June 24, 2022
Schedules of Controlled Substances: Placement of Methoxetamine (MXE) in Schedule I\Drug
DEA; June 6, 2022
Schedules of Controlled Substances: Placement of N-Ethylhexedrone, alpha-Pyrrolidinohexanophenone, 4-Methyl-alpha-ethylaminopentiophenone, 4′-Methyl-alpha-pyrrolidinohexiophenone, alpha-Pyrrolidinoheptaphenone, and 4′-Chloro-alpha-pyrrolidinovalerophenone in Schedule I
DEA; June 1, 2022
Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V
DEA; June 1, 2022
DEA TOX: Quarterly Report – 1st Quarter 2022
DEA; May 2022
NFLIS-Drug 2021 midyear report
National Forensic Laboratory Information System, Diversion Control Division
DEA; 32pp; April 2022
Synth-Opioids Real-Time Communication Network – 2021 annual report
Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I
DEA; April 11, 2022
Schedules of Controlled Substances: Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I; Final rule
DEA; April 7, 2022